ERBB2 and breast carcinoma: Indeed, the HER2‐low breast cancer subtype is currently targetable by trastuzumab deruxtecan [26], and basal‐like and molecular apocrine tumors are extensively investigated for sensitivity to DNA‐damaging agents (basal‐like tumors) and anti‐androgen agents (molecular apocrine tumors).